Efficacy and Safety Study of BG00012 With Methotrexate in Patients With Active Rheumatoid Arthritis

• Status: Completed
• Trial end date: 2010-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate whether the drug BG00012 can improve the symptoms of rheumatoid arthritis (RA) in patients who are already taking methotrexate for RA, but who still suffer symptoms of RA. The purpose is also to ensure that the combination of methotrexate is safe for patients to take and that any side effects are acceptable to patients with RA.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Biogen
• Treatments: Antirheumatic Agents; Dimethyl Fumarate; Methotrexate

Criteria

Inclusion Criteria:

• must be taking methotrexate

• inadequate response to at least one conventional DMARD

• swollen and tender joint count

Exclusion Criteria:

• previous treatment with TNF or any other biologic or prosorba column

Other criteria also apply.